KRAS and non-small cell lung carcinoma: Also, development of resistance to targeted therapies is related to plasticity in metabolic pathways associated with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in NSCLC (45, 46), a vulnerability which can be exploited in combination treatments (47).